马来酸曲美布汀治疗肠易激综合征的疗效及安全性

目的：临床验证马来酸曲美布汀（舒丽启能）治疗肠易激综合征（IBS）的疗效及安全性。方法：多中心开放基础上对照研究。选择IBS患者64例，空白对照治疗2周，15例临床症状缓解，49例进行丽启能治疗组po,200mg,tid疗程2周，观察腹痛、腹泻、排便异常、排便因难症状变化。结果：舒丽启能对腹痛治疗有效率为91．8％。排便异常效率为89．8％，腹泻有效率为86．6％，排便困难有效果率为81．8％，总体评估总有效率为81．6％。安全性研究未发现不良反应。结论：舒丽启能治疗IBS是安全有效。

The efficacy and safety oftrimebutine maleate in the treatment of irritable bowel syndrome

Objective:To validate the clinical safety and effic acy of trimebutine maleate(Cerekinon) in treatment of irritable bowel syndrome(I BS).Methods:64 patients with IBS were recruited into the study.Aft er 2 weeks placebo treatment 15 patients were excluded from the study due to sym ptoms relief.The balance of 49 patients were treated with Cerekinon 200mg,po,tid for 2 weeks.Results:After 2 weeks treatment,the following result s were obtained:91.8% reduction in abdominal pain;89.8% reduction in abnormal de fecation;86.6% reduction in diarrhoea;81.8% reduction in constipation;and a tota l effective rate 81.6%.No side effect was observed.Conclusion:Cere kinon is an effective agent for treatment of IBS.